Shih W J, Wierzbinski B, Collins J, Pearson T C, Magoun S, Ryo U Y
VA Medical Center, Lexington, Kentucky.
Clin Nucl Med. 1989 Oct;14(10):750-5. doi: 10.1097/00003072-198910000-00007.
For an evaluation of the clinical utility of prostate-specific antigen (PSA), 32 prostatic carcinoma patients (ages 54-76) and 13 nonprostatic carcinoma patients (ages 60-70) underwent PSA measurements and bone imaging. At the time of bone imaging, each patient's PSA value was measured by a monoclonal immunoradiometric assay. All 13 nonprostatic carcinoma patients (11 bronchogenic, 1 colon, and 1 urinary bladder) gave normal PSA values, although 6 had metastatic bone disease. The 32 prostatic cancer patients were divided into 2 groups of 16 each; PSA levels in Group 1 were abnormal (greater than or equal to ng/ml): PSA levels in Group 2 were normal (less than 4 ng/ml). In Group 1, bone images of 14 patients showed bone metastases; 6 of the 14 showed progression of metastases in a 6- to 12-month period. Two patients in Group 1 were negative for skeletal metastases. Twelve patients in Group 2 were negative for skeletal metastases; bone imaging in 1 showed regression of skeletal metastases; and 3 patients had unchanged bone lesion(s). The data indicate that PSA measurements may enhance bone imaging interpretation and provide valuable clinical monitoring of prostatic carcinoma. In the case of a patient with positive bone imaging and an unknown primary, PSA measurements may definitively determine if metastases originated from prostatic carcinoma.
为评估前列腺特异性抗原（PSA）的临床应用价值，32例前列腺癌患者（年龄54 - 76岁）和13例非前列腺癌患者（年龄60 - 70岁）接受了PSA检测和骨显像。在进行骨显像时，通过单克隆免疫放射测定法测量每位患者的PSA值。所有13例非前列腺癌患者（11例支气管癌、1例结肠癌和1例膀胱癌）的PSA值均正常，尽管其中6例有骨转移疾病。32例前列腺癌患者被分为两组，每组16例；第1组的PSA水平异常（大于或等于ng/ml）：第2组的PSA水平正常（小于4 ng/ml）。在第1组中，14例患者的骨显像显示有骨转移；其中14例中的6例在6至12个月期间出现转移进展。第1组中有2例患者骨转移呈阴性。第2组中有12例患者骨转移呈阴性；1例患者的骨显像显示骨转移消退；3例患者的骨病变无变化。数据表明，PSA检测可能会增强骨显像的解读，并为前列腺癌提供有价值的临床监测。对于骨显像阳性且原发灶不明的患者，PSA检测可能明确确定转移是否源于前列腺癌。
